Login to Your Account



Erytech expanding use, production of Graspa with $74.7M placing

By Nuala Moran
Staff Writer

Friday, April 14, 2017

LONDON – Three weeks after publishing positive phase IIb results for Graspa in pancreatic cancer, Erytech Pharma SA has pulled together a €70.4 million placing to finance preparations for phase III.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription